Aveanna Healthcare Q3 Revenue Rises 11.8%; Raises 2026 Financial Outlook

Aveanna Healthcare (AVAH) reported Q3 2026 revenue of $695.5M, up 11.8% YoY, with net income of $45.5M. Adjusted EBITDA rose 25.0% to $100.1M. The company raised full-year 2026 revenue guidance to over $2.695B and Adjusted EBITDA to over $374M, citing strong operating momentum.

Original reporting
Published Nov 13, 2026, 6:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVAH
Bullish
high confidence
Mentioned
$AVAH
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AVAHBullishMed
01

Why it matters

Earnings beat and guidance raise are likely to support a price rally, though debt levels and interest‑rate exposure remain concerns.

02

Market read

First‑time earnings and guidance disclosure for AVAH, providing fresh data for traders.

03

What to watch

Potential impact of interest‑rate caps and debt levels on future cash flow.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Aveanna Healthcare Holdings Inc. reported Q3 2026 results, showing revenue growth across all segments and raised its full‑year outlook.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Q3 2026 results posted with 11.8% revenue growth and raised full-year 2026 revenue and Adjusted EBITDA guidance.

Expected impact

likely upward pressure as market prices in higher revenue and EBITDA outlook

Evidence & confidence

First report of earnings and guidance, material numbers for a listed health‑care provider.

Market effects

May lift sentiment for the home‑care and health‑services sector.

US health‑care stocks could see modest gains.

Limited to U.S. listed health‑care providers.

Counterpoint

Guidance raise is modest; high leverage and interest‑rate exposure could limit upside.

Key entities

  • Aveanna Healthcare Holdings Inc.

    NASDAQ‑listed home‑care provider.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.

$AVAHHighAI 8/10

Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.